- Home
- INKT vs NTRB Comparison
INKT vs NTRB Comparison
Compare INKT & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | NTRB |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 57.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INKT | NTRB |
|---|---|---|
| Price | $12.34 | $4.44 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 11.8K | ★ 63.5K |
| Earning Date | 11-14-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,278,321.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $4.56 | $4.17 |
| 52 Week High | $76.00 | $11.78 |
Technical Indicators
Market Signals| Indicator | INKT | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 49.36 |
| Support Level | $11.28 | $4.25 |
| Resistance Level | $12.31 | $4.74 |
| Average True Range (ATR) | 0.53 | 0.22 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 84.77 | 71.94 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.